Advanced Renal Cell Carcinoma
Conditions
Brief summary
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib.
Detailed description
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC. The study is designed to compare the PFS, OS, ORR, DR, safety and tolerability, and kidney specific symptoms/health outcome measurements of tivozanib and sorafenib. Subjects will be randomized (1:1) to treatment with tivozanib or sorafenib and stratified by geographic region (North America/Western Europe, Central/Eastern Europe, or rest of the world); number of prior treatments (0 or 1); and number of metastatic sites/organs involved (1 or ≥ 2).
Interventions
Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
DRUGSorafenib
Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
Sponsors
AVEO Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. ≥ 18-years of age. 2. Subjects with recurrent or metastatic RCC. 3. Subjects must have undergone prior nephrectomy (complete or partial) for excision of the primary tumor. 4. Histologically or cytologically confirmed RCC with a clear cell component (subjects with pure papillary cell tumor or other non-clear cell histologies, including collecting duct, medullary, chromophobe, mixed tumor containing predominantly sarcomatoid cells, and unclassified RCC are excluded). 5. Measurable disease per the RECIST criteria Version 1.0. 6. Treatment naïve subjects or subjects who have received no more than one prior systemic treatment (immunotherapy, including interferon-alfa or interleukin-2 based therapy, chemotherapy, hormonal therapy or an investigational agent) for metastatic RCC. Postoperative or adjuvant systemic therapy will not be counted as a prior therapy unless recurrence is detected within 6 months of completion of treatment, in which case it will be counted as a prior therapy for metastatic disease. 7. ECOG performance status of 0 or 1, and life expectancy ≥ 3 months. 8. If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment. 9. Ability to give written informed consent and comply with protocol requirements.
Exclusion criteria
1. Any prior VEGF-directed therapy including VEGF antibody (eg, bevacizumab), VEGF receptor tyrosine kinase inhibitor (eg, sunitinib, sorafenib, axitinib, pazopanib, etc.), VEGF trap (eg, aflibercept), or any other agent or investigational agent targeting the VEGF pathway. 2. Any prior therapy with an agent targeting the mTOR pathway (eg, temsirolimus, everolimus, etc) 3. Primary CNS malignancies or CNS metastases; subjects with previously treated brain metastasis will be allowed if the brain metastasis have been stable without steroid treatment for at least 3 months following prior treatment (radiotherapy or surgery). 4. Any hematologic abnormalities (as noted in the protocol). 5. Any serum chemistry abnormalities (as noted in the protocol). 6. Significant cardiovascular disease. 7. Non-healing wound, bone fracture, or skin ulcer. 8. Active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, or other gastrointestinal condition with increased risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to administration of first dose of study drug. 9. Serious/active infection or infection requiring parenteral antibiotics. 10. Inadequate recovery from any prior surgical procedure or major surgical procedure within 4 weeks prior to administration of first dose of study drug. 11. Significant thromboembolic or vascular disorders within 6 months prior to administration of first dose of study drug. 12. Significant bleeding disorders within 6 months prior to administration of first dose of study drug. 13. Currently active second primary malignancy, including hematologic malignancies (leukemia, lymphoma, multiple myeloma, etc.), other than non-melanoma skin cancers, non-metastatic prostate cancer, in situ cervical cancer and ductal or lobular carcinoma in situ of the breast. Subjects are not considered to have a currently active malignancy if they have completed anti-cancer therapy and have been disease free for \>2 years. 14. Pregnant or lactating females. 15. History of genetic or acquired immune suppression disease such as HIV; subjects on immune suppressive therapy for organ transplant. 16. Life-threatening illness or organ system dysfunction compromising safety evaluation. 17. Requirement for hemodialysis or peritoneal dialysis. 18. Inability to swallow pills, malabsorption syndrome or gastrointestinal disease that severely affects the absorption of tivozanib or sorafenib, major resection of the stomach or small bowel, or gastric bypass procedure. 19. Psychiatric disorder or altered mental status precluding informed consent or necessary testing. 20. Sexually active pre-menopausal female subjects (and female partners of male subjects) must use adequate contraceptive measures, while on study and for 50 days after the last dose of study drug. Sexually active male subjects must use adequate contraceptive measures, while on study for at least 90 days after the last dose of drug. All fertile male and female subjects and their partners must agree to use a highly effective method of contraception (including their partner). Effective birth control includes (a) IUD plus one barrier method; or (b) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). (Note: Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are not considered effective for this study.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks. | Progression-Free Survival (PFS) is defined as the time from randomization to first documentation of objective tumor progression (progressive disease) or death due to any reasons whichever comes first. Disease progression per RECIST 1.0 criteria is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | Every 8 weeks from date of randomization until disease progression | Objective response rate (ORR) is defined as the percentage of subjects who have at least a 30% reduction in the sum of diameters per RECIST (Version 1.0). |
| Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | Assessed every 8 weeks from date of randomization until date of progression | Duration of response (DR) is defined as the time from the first documentation of objective tumor response to the first documentation of tumor progression per RECIST 1.0 or to death due to any cause. |
| Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | Date of randomization to date of death | Overall survival (OS) is defined as the time from the date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive. Subjects lacking data beyond randomization will have their survival times censored on the date of randomization. |
| To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | At Day 1 of each 28 day cycle throughout the course of the study, for an average of 11 months per subject | The Disease Related Symptom Scale of the Functional Assessment of Cancer Therapy - Advanced Kidney Cancer Symptom Index (FKSI-DRS) measured kidney specific symptoms on a 0-36 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The Functional Assessment of Cancer Therapy-General (FACT-G) measured general wellbeing scored on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The European Quality of Life-5 Dimensions (EQ-5D) measured patient health related quality of life scored on a 0-1 scale, with 0 being worse health state and 1 being perfect health state. The European Quality of Life-5 Dimensions Visual Analog Scales (EQ-5D VAS) measured patient health related quality of life on a visual analog scale from 0 to 100, with 0 being the worst and 100 being the best. These scales were self-administered by patients at the start of the visit. |
| Pharmacokinetics (Serum Concentrations) of Tivozanib | Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28 | Samples for tivozanib serum concentrations will be collected at the following time points: Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28. The serum concentrations of tivozanib were tabulated for individual subjects and summarized by nominal time using standard descriptive statistics (concentrations presented in ng/mL). |
| Safety and Tolerability of Tivozanib and Sorafenib | From start of treatment therapy to completion of treatment therapy, an average of 11 months | Dose reductions and interruptions were allowed for subjects taking tivozanib or sorafenib. Any modification of study drug administration, and the reason for such action, was clearly noted on the subject's eCRF. |
Countries
Argentina, Bulgaria, Canada, Chile, Czechia, France, Hungary, India, Italy, Poland, Romania, Russia, Serbia, Ukraine, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tivozanib (AV-951) tivozanib (AV-951): Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks. | 260 |
| Sorafenib Sorafenib: Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks. | 257 |
| Total | 517 |
Baseline characteristics
| Characteristic | Tivozanib (AV-951) | Sorafenib | Total |
|---|---|---|---|
| Age, Continuous | 59 Years | 59 Years | 59 Years |
| Sex: Female, Male Female | 75 Participants | 68 Participants | 143 Participants |
| Sex: Female, Male Male | 185 Participants | 189 Participants | 374 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 238 / 259 | 249 / 257 |
| serious Total, serious adverse events | 74 / 259 | 56 / 257 |
Outcome results
Primary
Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib
Progression-Free Survival (PFS) is defined as the time from randomization to first documentation of objective tumor progression (progressive disease) or death due to any reasons whichever comes first. Disease progression per RECIST 1.0 criteria is defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first. Disease progression was assessed every 8 weeks.
Population: ITT Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tivozanib (AV-951) | Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib | 11.9 Months |
| Sorafenib | Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib | 9.1 Months |
Secondary
Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib
Duration of response (DR) is defined as the time from the first documentation of objective tumor response to the first documentation of tumor progression per RECIST 1.0 or to death due to any cause.
Time frame: Assessed every 8 weeks from date of randomization until date of progression
Population: ITT Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tivozanib (AV-951) | Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | 15.0 Months |
| Sorafenib | Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | 12.9 Months |
Secondary
Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib
Objective response rate (ORR) is defined as the percentage of subjects who have at least a 30% reduction in the sum of diameters per RECIST (Version 1.0).
Time frame: Every 8 weeks from date of randomization until disease progression
Population: ITT Population
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tivozanib (AV-951) | Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | 33.1 percentage of participants |
| Sorafenib | Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | 23.3 percentage of participants |
Secondary
Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib
Overall survival (OS) is defined as the time from the date of randomization to date of death due to any cause. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive. Subjects lacking data beyond randomization will have their survival times censored on the date of randomization.
Time frame: Date of randomization to date of death
Population: ITT Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tivozanib (AV-951) | Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | 28.2 Months |
| Sorafenib | Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib | 30.8 Months |
Secondary
Pharmacokinetics (Serum Concentrations) of Tivozanib
Samples for tivozanib serum concentrations will be collected at the following time points: Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28. The serum concentrations of tivozanib were tabulated for individual subjects and summarized by nominal time using standard descriptive statistics (concentrations presented in ng/mL).
Time frame: Cycle 1, Day 1 (prior to dosing), Cycle 1, Day 15 (prior to dosing), Cycle 2, Day 1 (prior to dosing), and Cycle 2, Day 22-28
Population: All patients who had taken at least 1 dose of tivozanib and who had at least one measurable concentration value.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Tivozanib (AV-951) | Pharmacokinetics (Serum Concentrations) of Tivozanib | Cycle 1, Day 1 | 0 ng/mL |
| Tivozanib (AV-951) | Pharmacokinetics (Serum Concentrations) of Tivozanib | Cycle 1, Day 15 | 69.05 ng/mL |
| Tivozanib (AV-951) | Pharmacokinetics (Serum Concentrations) of Tivozanib | Cycle 2, Day 1 | 30.87 ng/mL |
| Tivozanib (AV-951) | Pharmacokinetics (Serum Concentrations) of Tivozanib | Cycle 2, Day 22-28 | 54.37 ng/mL |
Secondary
Safety and Tolerability of Tivozanib and Sorafenib
Dose reductions and interruptions were allowed for subjects taking tivozanib or sorafenib. Any modification of study drug administration, and the reason for such action, was clearly noted on the subject's eCRF.
Time frame: From start of treatment therapy to completion of treatment therapy, an average of 11 months
Population: Safety Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Tivozanib (AV-951) | Safety and Tolerability of Tivozanib and Sorafenib | Reasons for Dose Interruptions - Adverse Event | 50 Participants |
| Tivozanib (AV-951) | Safety and Tolerability of Tivozanib and Sorafenib | Reasons for Dose Reductions - Adverse Event | 36 Participants |
| Sorafenib | Safety and Tolerability of Tivozanib and Sorafenib | Reasons for Dose Interruptions - Adverse Event | 92 Participants |
| Sorafenib | Safety and Tolerability of Tivozanib and Sorafenib | Reasons for Dose Reductions - Adverse Event | 111 Participants |
Secondary
To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib
The Disease Related Symptom Scale of the Functional Assessment of Cancer Therapy - Advanced Kidney Cancer Symptom Index (FKSI-DRS) measured kidney specific symptoms on a 0-36 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The Functional Assessment of Cancer Therapy-General (FACT-G) measured general wellbeing scored on a 0-108 scale, with lower scores corresponding to worse overall QOL and higher scores corresponding to better overall QOL. The European Quality of Life-5 Dimensions (EQ-5D) measured patient health related quality of life scored on a 0-1 scale, with 0 being worse health state and 1 being perfect health state. The European Quality of Life-5 Dimensions Visual Analog Scales (EQ-5D VAS) measured patient health related quality of life on a visual analog scale from 0 to 100, with 0 being the worst and 100 being the best. These scales were self-administered by patients at the start of the visit.
Time frame: At Day 1 of each 28 day cycle throughout the course of the study, for an average of 11 months per subject
Population: ITT Population, excluding questionnaires that were not analyzable
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Tivozanib (AV-951) | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | FACT-G Total Score | 74.16 Score on a scale | Standard Error 0.785 |
| Tivozanib (AV-951) | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | FKSI-DRS Score | 28.71 Score on a scale | Standard Error 0.227 |
| Tivozanib (AV-951) | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | EQ-5D Weighted Health State Index | 0.67 Score on a scale | Standard Error 0.014 |
| Tivozanib (AV-951) | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | EQ-5D VAS | 71.50 Score on a scale | Standard Error 0.826 |
| Sorafenib | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | EQ-5D VAS | 68.49 Score on a scale | Standard Error 0.841 |
| Sorafenib | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | FACT-G Total Score | 73.05 Score on a scale | Standard Error 0.802 |
| Sorafenib | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | EQ-5D Weighted Health State Index | 0.66 Score on a scale | Standard Error 0.014 |
| Sorafenib | To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib | FKSI-DRS Score | 28.58 Score on a scale | Standard Error 0.233 |